Viridian announces offering of common stock, Series B preferred stock

Viridian Therapeutics announced that it has commenced an underwritten public offering of shares of its common stock and Series B preferred stock. Viridian intends to use the proceeds from the proposed underwritten public offering of its shares of common stock and Series B preferred stock, together with its cash, cash equivalents and short-term investments, to further its clinical development programs, as well as for working capital and general corporate purposes. Jefferies and Leerink Partners are acting as joint lead book-running managers for the proposed offering.